The Yuan requests your support! Our content will now be available free of charge for all registered subscribers, consistent with our mission to make AI a human commons accessible to all. We are therefore requesting donations from our readers so we may continue bringing you insightful reportage of this awesome technology that is sweeping the world. Donate now
BIO-Europe 2023 conference panel offers insights into AI’s ascent in pharma
By Oladimeji Ewumi  |  Feb 08, 2024
BIO-Europe 2023 conference panel offers insights into AI’s ascent in pharma
Image courtesy of and under license from
Experts in an AI panel session at the 2023 BIO-Europe winter conference highlighted some exciting biotech and pharma use cases in drug discovery for critical diseases while exploring the current regulatory outlook and other future possibilities. AI commentator Oladimeji Ewumi reports live.

MUNICH - Ed Saltzman, senior strategic advisor at UK-based Lumanity - a consulting company focused on the healthcare industry - moderated this deep dive session to discuss proven examples of biopharma companies successfully using artificial intelligence (AI) at the BIO-Europe Winter 2023, which ran from November 6-8 in Munich, Germany,

Panelists who convened at the ‘The rise of AI in pharma’ session on November 6 included Najat Khan, PhD, Chief Data Science Officer and Global Head of Strategy, Portfolio and Operations at Johnson & Johnson (J&J) New Jersey-based unit Janssen Research & Development, Richard Law, Chief Business Officer at British pharmatech Exscientia, Michelle Chen, Chief Business Officer at AI-powered biotech Insilico Medicine - which has headquarters in Hong Kong and New York - and Matthias Müllenbeck, Senior Vice President and Head of Global Business Development & Alliance Management at Germany’s Merck.

Saltzman: We are all aware that the pharma industry has a big problem - drug discovery and drug development. Now, drug commercialization has become incredibly risky - much riskier than it has ever been, and yet we still do many of those things more or less the same way [as] we've done them for the past two decades. All of this will force consideration of how we can reduce the terrible toll these things take on successfully developing drugs and getting them to patients, so I think AI has a big role. While I don't doubt the impact, I don't know what to look for, and I don't know what signposts we'll see that say AI is having an impact. So, my first question is, how would you characterize AI in biopharma today?

Müllenbeck: We all agree that AI in biotech and AI in big pharma are rapidly evolving on all fronts

The content herein is subject to copyright by The Yuan. All rights reserved. The content of the services is owned or licensed to The Yuan. Such content from The Yuan may be shared and reprinted but must clearly identify The Yuan as its original source. Content from a third-party copyright holder identified in the copyright notice contained in such third party’s content appearing in The Yuan must likewise be clearly labeled as such.
Continue reading
Sign up now to read this story for free.
- or -
Continue with Linkedin Continue with Google
Share your thoughts.
The Yuan wants to hear your voice. We welcome your on-topic commentary, critique, and expertise. All comments are moderated for civility.